Nausea was the most commonly reported adverse event with both agents, with slightly less persistent nausea in the liraglutide group than in the exenatide group.

两种药使用中报告频率最多的不良反应是呕吐，依拉鲁肽组相比依克那肽组持续呕吐的发生要稍轻些。

youdao

Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) is in phase III trials of Exenatide, a drug that promises to treat Type 2 diabetes.

FORBES: Magazine Article

Byetta (exenatide) is a relatively new drug and was approved to treat type 2 diabetes in 2005.

CNN: Diabetes drug Byetta tied to kidney problems, says FDA